Skip to main content
HARBIN GLORIA PHARMACEUTICALS Co., LTD logo

HARBIN GLORIA PHARMACEUTICALS Co., LTD — Investor Relations & Filings

Ticker · 002437 ISIN · CNE100000QG8 LEI · 300300K1ZDAXM6M73U33 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,133 across all filing types
Latest filing 2023-07-14 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 002437

About HARBIN GLORIA PHARMACEUTICALS Co., LTD

https://www.gloria.cc

Harbin Gloria Pharmaceuticals Co., Ltd. focuses on the research, development, manufacturing, and commercialization of diverse pharmaceutical products. The company specializes in therapeutic areas including cardiovascular and cerebrovascular diseases, orthopedics, oncology, and metabolic disorders. Its portfolio comprises chemical drugs, biological products, and specialized injections, with key products such as Alprostadil and Deer Melon Polypeptide. The organization prioritizes technological innovation through a dedicated R&D infrastructure aimed at developing both generic and innovative medications. It maintains multiple production facilities and an extensive distribution network to supply healthcare solutions for chronic and acute conditions.

Recent filings

Filing Released Lang Actions
2023年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2023 first extraordinary general meeting (临时股东大会) of Harbin Yuheng Pharmaceutical Co., Ltd. It includes information about the meeting date, attendance, voting results on various proposals, election of supervisors, and legal opinions confirming the validity of the meeting and resolutions. The content focuses on the official voting results and decisions made by shareholders at the meeting. There is no indication that this is a full annual or interim report, audit report, or earnings release. It is not a proxy solicitation or investor presentation. The document is not a brief announcement of a report publication but a full disclosure of voting outcomes. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length and detail support this classification with high confidence.
2023-07-14 Chinese
2023年第一次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the legality of the procedures and resolutions of a company's 2023 first extraordinary general meeting (临时股东大会). It details the convening, attendance, voting procedures, and results of the meeting. It does not contain financial statements or management discussion but focuses on the legal validation of the shareholder meeting and its resolutions. This type of document is typically classified as a Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting outcomes and confirms the legitimacy of the shareholder meeting procedures.
2023-07-14 Chinese
关于出售持有的广州誉衡生物科技有限公司全部股权的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Harbin Yuheng Pharmaceutical Co., Ltd. regarding the sale of its entire equity stake in Guangzhou Yuheng Biotechnology Co., Ltd. It includes transaction overview, parties involved, financial data of the target company, transaction terms, risk disclosures, audit and valuation reports, and independent director opinions. The content focuses on a capital transaction involving equity transfer and related financial and legal details. It is not a full annual or interim report, earnings release, or management discussion. It is a comprehensive capital/financing update about a significant equity sale. Therefore, the document fits best under Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement or a regulatory filing fallback. Confidence is high due to the detailed transaction and financial data provided.
2023-06-28 Chinese
关于召开2023年第一次临时股东大会的通知
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is a detailed notice about convening the 2023 first extraordinary general meeting (临时股东大会) of Harbin Gloria Pharmaceuticals Co., Ltd. It includes information about the meeting date, location, agenda items, voting procedures, and proxy forms. It does not contain financial statements or results but is an announcement of a shareholder meeting and related voting instructions. This fits the category of a shareholder meeting notice rather than a report or results announcement. Therefore, the appropriate classification is 'Declaration of Voting Results & Voting Rights Announcements (DVA)' or possibly 'Proxy Solicitation & Information Statement (PSI)'. However, since this document is a notice of the meeting and voting procedures rather than the solicitation materials or proxy statement, it aligns best with a meeting notice. Given the options, the closest match is 'Declaration of Voting Results & Voting Rights Announcements (DVA)' as it relates to shareholder voting matters. Confidence is high due to the clear meeting and voting focus and absence of financial data or report publication language.
2023-06-28 Chinese
关于监事辞职暨提名第六届监事会非职工代表监事候选人的公告
Board/Management Information Classification · 95% confidence The document is an announcement from Harbin Yuheng Pharmaceutical Co., Ltd. regarding the resignation of two supervisors and the nomination of candidates for the sixth supervisory board. It includes details about the resignations, legal compliance, and candidate qualifications. There are no financial statements, earnings data, or report attachments. The content focuses on changes in supervisory board members, which falls under management or board information disclosures. The document length is short (1783 characters), and it is not a report publication announcement or certification. Therefore, the appropriate classification is Board/Management Information (MANG).
2023-06-28 Chinese
资产评估报告
Audit Report / Information Classification · 95% confidence The document is titled '资产评估报告' which translates to 'Asset Valuation Report'. It is issued by an asset appraisal company and includes detailed valuation of shareholder equity of a company as of a specific valuation date (2022-12-31). The document contains extensive financial and operational details related to the valuation, including methods used (income approach, asset-based approach), assumptions, and conclusions. It is a comprehensive standalone asset valuation report, not an announcement or summary. It does not fit into categories like Annual Report, Interim Report, or Earnings Release, nor is it a regulatory filing or announcement. It is a specialized valuation report, which aligns best with the Audit Report / Information (AR) category, as it is a standalone report related to asset valuation and appraisal, which is a form of audit or assessment report. Confidence is high given the detailed nature and content of the document. FY 2022
2023-06-28 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.